BioCardia Secures Nasdaq Extension, Believes Delisting Risk Mitigated by $4.9M ATM Raise
BCDA is trading near its 52-week low of $0.777 (2.9% above the low) on light trading volume (0.3× avg).
Summary
BioCardia received a Nasdaq extension until October 7, 2026, to regain compliance with listing rules, following a $4.9 million ATM offering that the company believes has resolved its stockholders' equity deficiency.
Key Events · Corporate Governance and Compliance · BCDA
-
Nasdaq Delisting Extension Granted
Nasdaq granted an extension until October 7, 2026, for BioCardia to regain compliance with the minimum $2.5 million stockholders' equity requirement, following a prior delisting notice on April 15, 2026.
-
$4.9 Million Capital Raise
The company sold 4,004,330 shares through an At-The-Market (ATM) offering between April 1 and June 5, 2026, at an average price of $1.27 per share, generating net proceeds of $4.9 million.
-
Belief of Compliance
BioCardia believes these ATM sales have enabled it to regain compliance with Nasdaq's stockholders' equity rule, temporarily mitigating the immediate delisting threat.
Analysis · BCDA · Life Sciences
BioCardia, facing imminent delisting due to low stockholders' equity and a critical cash runway, has received an extension from Nasdaq until October 7, 2026. The company believes it has regained compliance by raising $4.9 million through an At-The-Market (ATM) offering, which involved selling shares at an average price of $1.27. While this capital raise is highly dilutive, it provides a crucial temporary reprieve from delisting and extends the company's financial runway, allowing more time to address its underlying financial challenges.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCDA was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $0.78 to $2.45. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.